var data={"title":"Dextranomer and hyaluronic acid or derivatives: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dextranomer and hyaluronic acid or derivatives: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/528410?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dextranomer-and-hyaluronic-acid-or-derivatives-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dextranomer and hyaluronic acid or derivatives: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809154\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Deflux;</li>\n      <li>Solesta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809159\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Skin and Mucous Membrane Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809220\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Fecal incontinence (Solesta):</b> Submucosal injection: 4 mL given as 4 x 1 mL injections in the anal canal in the following order: posterior, left lateral, anterior, and right lateral (maximum dose: 4 mL per treatment session); if inadequate response, may repeat &ge;4 weeks after first injection with the point of injection made in between the initial injections, shifted one-eighth of a turn (eg, left posterolateral, left anterolateral, right anterolateral, and right posterolateral).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683377\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Vesicoureteral reflux (Deflux):</b> Children &ge;1 year of age and Adolescents: Submucosal injection: 0.5 to 1 mL single injection in the bladder near the ureteral orifice; if the ureteral orifice does not completely coapt with a single injection, a second more distal intra-ureteral injection or a sub-ureteral implantation can be performed. Safety and effectiveness of &gt;6 mL (3 mL at each ureteral orifice) at the same treatment session have not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809221\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809222\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809223\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809227\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, gel:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Deflux: Dextranomer 50 mg and hyaluronic acid 15 mg per 1 mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solesta: Dextranomer 50 mg and sodium hyaluronate 15 mg per 1 mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809158\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809224\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For submucosal injection; do <b>not</b> administer intravascularly (may cause vascular occlusion). Refer to product labeling for detailed preparation and administration instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflux: In general, the bladder is semi-filled to allow for good visualization of the ureteral orifice(s) and to avoid tension within the submucosal layer of the ureter secondary to overdistension. Using a cystoscope, inject in the urinary bladder (close proximity to the ureteral orifice). A voiding cystourethrogram (VCUG) is suggested in the post treatment follow up to ascertain whether the reflux remains. If the original injection needs to be reinforced, further treatments may be administered. For previously treated patients, the injection sites from the previous procedure may still be visible; an augmentation of prior intraureteric injections can be performed or further enhanced with a subureteral injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solesta: Using an anoscope, inject slowly in the proximal part of the high pressure zone of the anal canal about 5 mm above the dentate line; avoid injection in midline of anterior wall of rectum in men with large prostates. Administer enema immediately prior to procedure to evacuate the anorectum and cleanse injection site with antiseptic. Use of prophylactic antibiotics is recommended. After injection, patient is to rest for ~1 hour (observe for bleeding or other treatment related symptoms). Confirming placement of gel by imaging may be of benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809161\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fecal incontinence (Solesta only): </b>Treatment of fecal incontinence in patients &ge;18 years of age who have failed to respond to conservative therapy (eg, diet, fiber therapy, antimotility medications).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vesicoureteral reflux (Deflux only):</b> Treatment of vesicoureteral reflux (VUR) grades II to IV in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809195\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Rectal pain (&le;17%; includes anorectal discomfort)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (2% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (&le;2%), pain (&le;1%), painful defecation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anal hemorrhage (&le;4%), diarrhea (&le;4%), rectal discharge (&le;4%), proctitis (&le;3%), anorectal pain (2%), constipation (&le;2%), perirectal abscess (&le;2%), pruritus ani (&le;2%), rectal disease (prolapse: &le;2%), lower abdominal pain (1%), abdominal distress (&le;1%), abdominal pain (&le;1%; including guarding/rigidity), anal abscess (&le;1%), anal fissure (&le;1%), bowel urgency (&le;1%), gastrointestinal obstruction (rectum: &le;1%), nausea (&le;1%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract dilation (ureter: &le;4%), dyspareunia (&le;1%), dysuria (&le;1%), pollakiuria (&le;1%), urinary incontinence (&le;1%), urinary urgency (&le;1%), urination disorder (vesicoureteral reflux: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Rectal hemorrhage (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (&le;8%), pain at injection site (&le;5%), injection site nodule (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distention, alopecia, application site reaction (implant migration), back pain, bacteremia (<i>Escherichia coli</i>), benign prostatic hypertrophy, bladder mucosa irritation, C-reactive protein increased, cyst at injection site, dermatitis, diaphoresis, fatigue, fecal impaction, fecal incontinence, foreign body reaction, gastrointestinal motility disorder, gastrointestinal pain, gastrointestinal symptoms (mass), genital lesion (prolapse), genital pain (vulvovaginal), hematuria, hemorrhoids, hypertonia (bladder), IgA vasculitis, injection site lesion, injection site reaction (including inflammation at injection site, irritation at injection site, pustules at injection site, swelling at injection site), mass (pelvic), mechanical complication of genitourinary device (calcification), mucosal inflammation, muscle spasm (rectum), musculoskeletal pain, neoplasm (pelvic), perineal pain, pyelonephritis, upper respiratory tract infection, ureteral obstruction (with/without hydronephrosis), urinary frequency, urinary retention, vaginal discharge</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809162\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflux: Non-functional kidneys; hutch diverticulum; ureterocele; active voiding dysfunction; ongoing UTI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solesta: Hypersensitivity to hyaluronic acid-based products, dextran, or any component of the formulation; active inflammatory bowel disease; immunodeficiency disorders or ongoing immunosuppressive therapy; prior pelvic radiation; significant mucosal or full thickness rectal prolapse; active anorectal conditions (eg, abscess, fissure, sepsis, bleeding, proctitis, infection); anorectal atresia, tumors, stenosis, or malformation; rectocele; rectal varices; existing anorectal implant (other than Solesta).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809178\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Bleeding risk at injection site is increased in patients with bleeding diathesis or in patients using anticoagulant or antiplatelet agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia: Solesta: Avoid injection in the midline of the anterior rectal wall in men with enlarged prostate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Do not administer intravascularly; injection into blood vessels may cause vascular occlusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Deflux: Treatment of duplex systems has not been prospectively studied. Ureters with grossly dilated orifices may render the patient unsuitable for treatment. Do not inject if the patient is known to be allergic to hyaluronic acid-based products or dextran.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Solesta: Safety and efficacy have not been investigated in patients with complete external sphincter disruption, significant chronic anorectal pain, rectal anastomosis &lt;12 cm from anal verge, anorectal surgery within past 12 months, hemorrhoid treatment with rubber band within 3 months, anorectal implants and previous injection therapy, stapled transanal rectal resection, or stapled hemorrhoidectomy. Durability has not been studied past 36 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Should only be administered by a physician familiar with anorectal procedures and who has been trained and certified in the Solesta injection procedure or in the use of a cystoscope and trained in the technique of subureteric and/or intraureteric injections (with Deflux or other materials).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50472813\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50472810\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87453&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683249\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Safety for use in pregnant women has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683250\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dextranomer and hyaluronate derivatives are present in breast milk. Safety for use in breastfeeding women has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683382\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Excessive bleeding and pain (during and after treatment).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809202\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fecal incontinence: Reduces frequency of fecal incontinence episodes; believed to work by building or bulking up tissue in the anal area to narrow the opening of the anus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dextranomer is a network of dextran-sucrose beads possessing a great many exposed hydroxy groups; when this network is applied to an exudative wound surface, the exudate is drawn by capillary forces generated by the swelling of the beads, with vacuum forces producing an upward flow of exudate into the network; sodium hyaluronate provides viscosity and facilitates injection of the dextranomer microspheres.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicoureteral reflux: Injection in the urinary bladder creates increased tissue bulk thereby providing coaptation of the distal ureter during filling and contraction of the bladder; the dextranomer microspheres are gradually surrounded by host connective tissue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570461\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Solesta Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-15 mg/mL (1 mL): $1470.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provided represent a median AWP and/or AAWP price for the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for charging or reimbursement functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777317\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Deflux (DE);</li>\n      <li>Redexis (ID);</li>\n      <li>Redexis Ultra (ID);</li>\n      <li>Zuidex (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Deflux (dextranomer and sodium hyaluronate) [prescribing information]. Rochester, NY: Salix Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solesta (dextranomer and sodium hyaluronate) [prescribing information]. Rochester, NY: Salix Pharmaceuticals; April 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87453 Version 34.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15809154\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15809159\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15809220\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50683377\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15809221\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15809222\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15809223\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15809227\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15809158\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15809224\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15809161\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15809195\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15809162\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15809178\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50472813\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50472810\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50683249\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50683250\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50683382\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15809202\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570461\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777317\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87453|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dextranomer-and-hyaluronic-acid-or-derivatives-patient-drug-information\" class=\"drug drug_patient\">Dextranomer and hyaluronic acid or derivatives: Patient drug information</a></li></ul></div></div>","javascript":null}